Navigation Links
New Study in The Journal of Maternal-Fetal and Neonatal Medicine Shows Fetal Cell-Free DNA in Maternal Blood Unaffected by Trisomy Risk
Date:8/27/2012

SAN JOSE, Calif., Aug. 27, 2012 /PRNewswire/ -- A study published in The Journal of Maternal-Fetal and Neonatal Medicine demonstrates that the fraction of fetal cell-free DNA (cfDNA) in maternal blood is unaffected by the mother's presumed risk for trisomy, offering support for the use of non-invasive prenatal testing (NIPT) for detecting genetic conditions such as Down syndrome in a broad patient population. Lead and senior authors of the study were Dr. Herb Brar, Director of Riverside Perinatal Diagnostics Center, and Dr. Mary Norton, Professor of Obstetrics and Gynecology, Lucile Packard Children's Hospital at Stanford University, respectively.

(Photo: http://photos.prnewswire.com/prnh/20120827/NE62428LOGO )

Results of the study, a post-hoc comparative analysis of the previously published "Non-invasive Chromosomal Evaluation" (NICE) study, showed that there were no significant differences in the fraction of fetal cfDNA in maternal blood in women who were stratified into three different trisomy risk groups based on maternal age, prenatal screening results or nuchal translucency measurement. The amount of fetal cfDNA in maternal blood is the principal factor in successfully detecting trisomies with NIPT. Trisomy refers to the presence of three chromosomes rather than two. Certain trisomies are known to cause genetic conditions. The study is available at: http://informahealthcare.com/doi/abs/10.3109%2F14767058.2012.722731

"The results of this study were particularly significant because they showed that fetal fraction of cfDNA does not vary significantly among pregnant women regardless of their predetermined trisomy risk," said Dr. Herb Brar. "This adds to the growing amount of research that suggests NIPT can offer an effective prenatal screening option in the general pregnant population."

NIPT is a new screening option that analyzes cell-free fetal DNA circulating in maternal blood to evaluate the risk of having a baby with Down syndrome and other common genetic conditions. It involves a single blood draw as early as 10 weeks' gestation and delivers a greater than 99 percent detection rate for trisomy 21, which causes Down syndrome. NIPT, using the Harmony™ Prenatal Test, also has shown to have fewer false positive test results; up to 50 times less than traditional prenatal screening options such as maternal serum screening.

Previous studies of the entire cohort of the NICE study demonstrated that fetal fraction did not vary with race, ethnicity, maternal age, or trisomy type. It also showed that the fraction of fetal cfDNA was similar in pregnancies of gestational ages between 10 and 22 weeks. The NICE study was a prospective cohort study of more than 4,000 pregnant women of at least 10 weeks' gestational age across 50 clinical sites internationally. The study evaluated the performance of Ariosa Diagnostics' Harmony Prenatal Test in detecting fetal trisomy 21 and 18, which cause Down syndrome and Edwards syndrome, respectively.  The NICE study evaluated any patient undergoing invasive prenatal testing, such as chorionic villus sampling (CVS) or amniocentesis, not just those who were determined to be at higher risk of having a baby with a genetic condition.

"We believe strongly that scientific research supports NIPT as a screening option for any pregnant woman, empowering them and their physicians to make the best decisions for individual circumstances. This is simply good patient care," said Ariosa Diagnostics CEO Ken Song, M.D. "NIPT has proven effective in thousands of patients, with a high accuracy and low false positive rate of less than 0.1% for each trisomy tested. It offers several advantages over traditional screening tests and can more appropriately triage those women who should undergo invasive procedures, namely amniocentesis and CVS, which carry a small risk of miscarriage."

About Ariosa Diagnostics (formerly Aria Diagnostics)

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Ariosa's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.


'/>"/>
SOURCE Ariosa Diagnostics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
2. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
3. Ocular Therapeutix Commences Pilot Phase II Travoprost Punctum Plug Study for the Treatment of Glaucoma
4. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
5. Staffing and Performance Benchmarks for Regulatory Function Highlight New Medical Device Study
6. Varian Medical Systems to Support an NCI-Sponsored Phase III Study Comparing Radiosurgery with Surgery for the Treatment of Early-Stage High-Risk, Operable Non-Small Cell Lung Cancer
7. New In Vitro Study Data Show That Wound Dressing With Silver Kills Multidrug-Resistant Organisms
8. Unprecedented Study shows Berlin Heart device provides life-saving "bridge" for young children and babies
9. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
10. German-based Contract Research Organization Verum.de Opens US Office to Expand Clinical Study Services in Central and Eastern Europe for American Pharma and Biotech
11. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):